Keyword Analysis & Research: nejm oncology

Keyword Analysis

Keyword	CPC	PCC	Volume	Score	Length of keyword
nejm oncology	1.07	0.5	2654	60	13
nejm	0.58	0.2	9836	85	4
oncology	1.28	0.1	1230	43	8

Keyword Research: People who searched nejm oncology also searched

Keyword	CPC	PCC	Volume	Score
nejm oncology jobs	1.89	0.9	398	82
nejm oncology	0.86	0.2	7972	77
nejm oncology journal watch	0.02	0.4	4614	25
nejm oncology articles	0.59	0.5	3382	59
nejm hematology oncology jobs	0.81	0.3	9340	58
nejm career center oncology	1.46	0.6	3112	4
nejm hematology oncology	1.53	0.5	9501	78
nejm radiation oncology jobs	1.85	1	1803	20
nejm oncology clinical trial	1.12	0.6	8284	80

Search Results related to nejm oncology on Search Engine

Hematology/Oncology | The New England Journal of Medicine
nejm.org

https://www.nejm.org/browse/specialty/hematology-oncology

WEBMar 13, 2024 · Explore Hematology/Oncology articles from The New England Journal of Medicine.

DA: 4 PA: 27 MOZ Rank: 48

Cancer | The New England Journal of Medicine
nejm.org

https://www.nejm.org/browse/topic/cancer

WEBJan 11, 2024 · Cancer | The New England Journal of Medicine. 1-20 of 471 results. Newest. Original Article. VOL. 390 NO. 2. Jan 11, 2024. CME. Repotrectinib in ROS1 Fusion–Positive Non–Small-Cell Lung Cancer....

DA: 98 PA: 59 MOZ Rank: 73

Hematology/Oncology General - The New England Journal of Medicine
nejm.org

https://www.nejm.org/browse/topic/hematology-oncology-general

WEBApr 4, 2024 · Explore Hematology/Oncology General articles from The New England Journal of Medicine

DA: 6 PA: 67 MOZ Rank: 91

Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2202170

WEBApr 11, 2022 · Nivolumab, a fully human anti–programmed death 1 (PD-1) antibody, restores the function of existing antitumor T cells, and chemotherapy enhances antitumor immunity through direct or indirect...

DA: 70 PA: 90 MOZ Rank: 14

Preoperative Treatment of Locally Advanced Rectal Cancer | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2303269

WEBPublished June 4, 2023. N Engl J Med 2023;389: 322 - 334. DOI: 10.1056/NEJMoa2303269. VOL. 389 NO. 4. Abstract. Background. Pelvic radiation plus sensitizing chemotherapy with a...

DA: 21 PA: 58 MOZ Rank: 16

Alectinib in Resected ALK-Positive Non–Small-Cell Lung Cancer | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2310532

WEBApr 10, 2024 · Platinum-based chemotherapy is the recommended adjuvant treatment for patients with resectable, ALK -positive non–small-cell lung cancer (NSCLC). Data on the efficacy and safety of adjuvant ...

DA: 51 PA: 64 MOZ Rank: 21

Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2302312

WEBMar 27, 2023 · DOI: 10.1056/NEJMoa2302312. VOL. 388 NO. 23. Abstract. Background. Standard first-line chemotherapy for endometrial cancer is paclitaxel plus carboplatin. The benefit of adding pembrolizumab to...

DA: 38 PA: 24 MOZ Rank: 9

Hematology/Oncology General | NEJM Evidence
nejm.org

https://evidence.nejm.org/browse/topic/hematology-oncology-general

WEBMar 26, 2024 · Hematology/Oncology General | NEJM Evidence. 1-20 of 36 results. Newest. Editorial. VOL. 3 NO. 4. Mar 26, 2024. Reflecting the Real World of Cancer Care — The Impact of Broadening Trial...

DA: 78 PA: 86 MOZ Rank: 50

The On- and Off-Ramps of Oncology Accelerated Approval | NEJM
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMp2208954

WEBSep 21, 2022 · To address ongoing concerns about the implementation of the FDA’s Accelerated Approval pathway in oncology, a comprehensive strategy is needed — one that equally emphasizes “on-ramp” and...

DA: 100 PA: 89 MOZ Rank: 36

Treatments in Oncology | NEJM Evidence
nejm.org

https://evidence.nejm.org/browse/topic/treatments-in-oncology

WEBMay 10, 2023 · Treatments in Oncology | NEJM Evidence. Filters. 1-11 of 11 results. Newest. Original Article. VOL. 2 NO. 6. May 15, 2023. FREE. Ropeginterferon versus Standard Therapy for Low-Risk Patients...

DA: 65 PA: 46 MOZ Rank: 28